Antibody-drug conjugates at ASCO 2027
Jun 4–8, 2027 Chicago, IL ~44k attendees Website
9 organizations at ASCO 2027 present work in antibody-drug conjugates. 9 of them have their own page in this guide. As of Oct 8, 2026.
Showing 1–9 of 9 organizations
| Organization | ASCO 2027 Attendance |
|---|---|
AbbVie North Chicago, IL | |
Global drugmaker whose cancer medicines include venetoclax and ibrutinib for blood cancers and the ADC mirvetuximab soravtansine for ovarian cancer. | Booth Exhibiting at Booth 27033 |
AstraZeneca Cambridge, UK | |
Global drugmaker with cancer medicines across lung, breast, blood and other cancers, including targeted therapies, immunotherapy and ADCs. | Booth Exhibiting at Booth 19029 |
BioNTech Mainz, Germany | |
Immunotherapy company developing mRNA cancer vaccines, a PD-L1/VEGF bispecific antibody, antibody-drug conjugates and CAR-T cell therapies. | Booth Exhibiting at Booth 24103 |
Daiichi Sankyo Tokyo, Japan | |
Japanese drugmaker known for antibody-drug conjugates, including trastuzumab deruxtecan (Enhertu) and datopotamab deruxtecan, for breast, lung and gastric cancers. | Booth Exhibiting at Booth 27073 |
Genmab Copenhagen, Denmark | |
Antibody drug developer behind epcoritamab for lymphoma and tisotumab vedotin for cervical cancer, with ADCs and bispecifics in development. | Booth Exhibiting at Booth 27131 |
Gilead and Kite Foster City, CA | |
Gilead and its cell therapy company Kite, offering the ADC sacituzumab govitecan for breast cancer and CAR-T therapies for lymphoma and leukemia. | Booth Exhibiting at Booth 23001 |
Immunome Bothell, WA | |
Clinical-stage oncology company with varegacestat in Phase 3 for desmoid tumors, a ROR1-targeted ADC and a FAP-targeted radioligand. | Booth Exhibiting at Booth 34164 |
Merck Rahway, NJ | |
Global drugmaker behind the PD-1 antibody pembrolizumab (Keytruda), with cancer trials in over 30 tumor types and a growing ADC pipeline. | Booth Exhibiting at Booth 14013 |
Pfizer New York, NY | |
Global drugmaker whose oncology portfolio spans ADCs from Seagen, small molecules, bispecifics and immunotherapies for breast, prostate, bladder, lung and blood cancers. | Booth Exhibiting at Booth 30071 · Pfizer Oncology |
Instantly find 20 buyers in antibody-drug conjugates
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Browse ASCO 2027 by
Organization type
Focus
- Clinical trials 58
- Biomarkers and genomics 44
- AI and data 38
- Blood cancers 36
- Lung cancer 28
- Genitourinary cancers 24
- Gastrointestinal cancers 21
- Breast cancer 18
- Immunotherapy 17
- Imaging and radiation 17
- Patient support and survivorship 14
- Antibody-drug conjugates 9
- Cell and gene therapy 8
- Melanoma and skin cancers 7
- Gynecologic cancers 6
Exhibit hall
Everyone
Not affiliated with the American Society of Clinical Oncology. Organization details are derived from ASCO’s published exhibitor list and each exhibitor’s own profile and website. Submit a correction